06. October 2017
MTG as protein labeling tool
Read more
06. October 2017
Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
Read more |
Document
03. August 2017
Artikel in DZG Aktuell 03/2017 über die Entwicklung eines Zöliakie Medikaments (deutsch)
Read more |
Document
11. July 2017
ELISA for detection of TG6 autoantibodies
Read more
18. May 2017
Chromogenic tissue transglutaminase activity assay
Read more
02. May 2017
Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
Read more |
Document
02. May 2017
Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
Read more |
Document
Successful ISO9001:2015 recertification
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering